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In a hospital-based observational study in Germany, 
we investigated children admitted to pediatric intensive care 
units and deaths caused by conﬁ  rmed pandemic (H1N1) 
2009 to identify risk factors and outcomes in critically ill 
children. Ninety-three children were eligible for our study, 
including 9 with hospital-acquired infections. Seventy-ﬁ  ve 
percent had underlying chronic medical conditions; neu-
rodevelopmental disorders were most prevalent (57%). The 
proportion of patients having >1 risk factor increased with 
age in years (odds ratio 1.21, p = 0.007). Of 15 deaths, 
11 occurred in a pediatric intensive care unit (case-fatality 
rate 12%, 95% conﬁ  dence interval 6%–21%). Only 9% of 
the children had been vaccinated against pandemic (H1N1) 
2009; all survived. Our results stress the role of underly-
ing risk factors, especially neurodevelopmental disorders, 
and the need for improving preventive measures to reduce 
severe disease and adverse outcomes of pandemic (H1N1) 
2009 in children.
T
he novel strain of inﬂ   uenza known as pandemic 
(H1N1) 2009 virus that originated in Mexico and the 
United States resulted in the ﬁ  rst pandemic of the 21st cen-
tury. Cases were observed in 214 countries, and 18,097 
laboratory-conﬁ  rmed deaths caused by this virus have been 
reported (1). In Germany, where the ﬁ  rst cases were con-
ﬁ  rmed on April 29, 2009, the number of reported cases was 
226,158 (including 255 deaths) as of May 18, 2010 (2).
Children were particularly affected by pandemic 
(H1N1) 2009. This ﬁ  nding is evident in the age distribution 
of patients, which is skewed toward younger age groups, 
and in high hospitalization rates for children identiﬁ  ed in 
many settings worldwide (3–5). Severity has been most-
ly assessed in terms of admission to intensive care units 
(ICUs) and case-fatality rates. In a cohort study in Aus-
tralia and New Zealand, the highest age-speciﬁ  c incidence 
rate for ICU admission was for children <1 year of age (6). 
Observational studies in ICU settings in the early pandemic 
phase in Mexico (7) and Canada (8) highlighted high rates 
of adolescents among critically ill patients.
Studies conducted in pediatric ICU (PICU) settings 
originate predominantly from the Americas (9–11). In Eu-
rope, Lister et al. summarized experiences from 4 ICUs in 
the United Kingdom and identiﬁ  ed 13 critically ill children 
with pandemic (H1N1) 2009 during June–July 2009 (12). 
These studies and national surveillance systems contrib-
uted to a better understanding of determinants and risk fac-
tors for severe disease in children. However, information 
from countries in Europe about severe cases of pandemic 
inﬂ  uenza (H1N1) 2009 in children who are particularly 
vulnerable is still limited (12,13). To obtain information on 
risk factors, course of disease, and outcome of critically 
ill children with pandemic (H1N1) 2009, we prospectively 
performed a nationwide observational study covering the 
fall wave of pandemic (H1N1) 2009 in Germany.
Methods
Study Design
We investigated cases of critically ill children with 
conﬁ  rmed pandemic (H1N1) 2009 in pediatric hospitals 
in Germany. The 375 study sites participating in the es-
tablished nationwide active surveillance network Survey 
Center for Rare Pediatric Diseases in Germany (ESPED) 
comprise all pediatric hospitals in Germany.
The study included pediatric cases of pandemic (H1N1) 
2009 reported during August 2009–April 30, 2010. Cases 
were deﬁ  ned as illness in patients <15 years of age who had 
a laboratory-conﬁ  rmed infection with pandemic (H1N1) 
2009 virus (determined by PCR, virus isolation, or antigen 
detection) and were admitted to a PICU or died.
Severe Cases of Pandemic (H1N1) 
2009 in Children, Germany 
Mathias Altmann, Lena Fiebig, Jana Soyka, Rüdiger von Kries, Manuel Dehnert, and Walter Haas
Author afﬁ  liations: Robert Koch Institute, Berlin, Germany (M. Alt-
mann, L. Fiebig, J. Soyka, M. Dehnert, W. Haas); and Ludwig-Max-
imilians-Universität, Munich, Germany (R. von Kries)
DOI: 10.3201/eid1702.101090Severe Cases of Pandemic (H1N1) 2009 in Children
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 2, February 2011  187 
Data Collection
A structured questionnaire, adapted from an earlier 
study on seasonal inﬂ  uenza by Liese et al. (14), was dis-
tributed to the hospitals that reported cases, completed by 
the treating physician, and collected by the ESPED study 
center. Monthly reporting was requested even if no cases 
were identiﬁ  ed. Up to 3 reminders were sent if question-
naires were not returned. To take into account the report-
ing delay, we included reports received by the study center 
until the end of April 2010. Of 211 distributed question-
naires requested by 132 hospitals, 176 (83%) were re-
turned to the study center (Figure 1). After excluding 2 
patients with cases who had been notiﬁ  ed twice and 81 
questionnaires from persons who did not fulﬁ  ll the case 
deﬁ   nition, there remained 93 (53%) eligible question-
naires from 55 hospitals. Data were double entered into 
an electronic database by using EpiData software (Epi-
Data Association, Odense, Denmark). Individual datasets 
were inspected for missing information, plausibility, and 
data entry errors. The contact persons of the participat-
ing hospitals were notiﬁ  ed up to 2 times when data were 
incomplete in the questionnaire form.
The structured questionnaire included patient informa-
tion; data on the hospital stay; clinical signs and symptoms 
of illness; clinical and laboratory diagnosis; speciﬁ  c treat-
ments; underlying chronic medical conditions (chronic re-
spiratory diseases, cardiac diseases, immunodeﬁ  ciency and 
neurodevelopmental disorders, including developmental 
delay, cerebral palsy, epilepsy, and other cognitive disor-
ders); status of inﬂ  uenza vaccination; and complications 
of the disease. Answer categories were predetermined, but 
other diagnoses and concurrent conditions could addition-
ally be speciﬁ  ed by the respondents as free text.
Statistical Analysis
Descriptive statistics comprised the calculation of me-
dian and interquartile ranges (IQRs) for continuous vari-
ables and absolute numbers and proportions (together with 
95% binomial exact conﬁ  dence intervals [CIs] where ap-
propriate) for categorical variables. For the calculation of 
inpatient periods, patients were excluded if they had ac-
quired pandemic (H1N1) 2009 while hospitalized. Com-
parative analyses were performed on the basis of the Wil-
coxon rank-sum test for continuous variables and Fisher 
exact test for categorical variables only for patients admit-
ted to a PICU. Odds ratios (ORs) and 95% CIs were cal-
culated. Logistic regression was performed for continuous 
independent variables. All reported p values were 2-sided, 
and p<0.05 was considered signiﬁ  cant. Statistical analyses 
were performed by using Stata 11.0 (StataCorp LP, College 
Station, TX, USA).
Data Protection and Ethical Clearance
Adherence to national data protection laws was ap-
proved by the Federal Commissioner for Data Protection 
and Freedom of Information of Germany. Ethical approval 
was granted by the Ethics Committee, Charité, Univer-
sitätsmedizin, Berlin, Germany.
Results
Characteristics of Study Population
During the study period, we included 93 critically ill 
children with conﬁ  rmed pandemic (H1N1) 2009. Their 
dates of disease onset were September 21, 2009–February 
23, 2010; a peak in November 2009 included 58% of the 
cases (Figure 2). Sixty percent of the patients were boys. 
The age distribution is shown in Figure 3. Median age 
was 4.5 years (IQR 1.3–9.3 years), 19 (20%) were <1 
year of age, and 16 (17%) children were <6 months of 
age. Seventy-eight patients survived and 15 died. Among 
those who died, 4 patients were not admitted to a PICU 
(Figure 1). Nine patients, of whom 1 died, had acquired 
pandemic (H1N1) 2009 while hospitalized. The PICU 
cohort comprised 89 patients with a case-fatality rate of 
12% (95% CI 6%–21%). The 89 reported patients cor-
respond to an incidence rate for severe PICU-admitted 
cases of 27.8 cases/million children in infants <1 year of 
age and 8.0 cases/million children in children <15 years 
of age (all children of the same age group). No difference 
Figure 1. Overview of study participation and participant groups 
among children with severe pandemic (H1N1) 2009, Germany, 
2009–2010. PICU, pediatric intensive care unit.RESEARCH
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was found in the age distribution between survivors and 
those who died.
Underlying Chronic Medical Conditions 
and Vaccination Status
Seventy-ﬁ  ve percent (67/89 with available informa-
tion) of the patients had ≥1 underlying chronic medical 
condition known as a risk factor for seasonal inﬂ  uenza. The 
age distribution by presence or absence of ≥1 underlying 
chronic medical condition is shown in Figure 4. The pro-
portion of patients having ≥1 risk factor increased with age 
in years (OR 1.2, 95% CI 1.1–1.4; p = 0.007). Neurodevel-
opmental disorders were most frequently reported (57% of 
the cases), followed by chronic respiratory diseases (38%), 
immunodeﬁ   ciency (16%), and cardiac diseases (13%) 
(Table 1). Neurodevelopmental disorders were associated 
with a chronic respiratory disease in 60% (25/42) of the 
cases and were present in 79% (11/14) of those who died. 
Among the 53 children >6 months of age for whom infor-
mation was available, 5 patients (9%) had been vaccinated 
against pandemic (H1N1) 2009; all of them survived.
Clinical Manifestations
Pneumonia was the most frequent clinical diagnosis. 
It was documented in 70 (75%) of 93 patients and was the 
only diagnosis for 37% of them. The second most frequent 
diagnosis was acute respiratory distress syndrome (ARDS) 
in 22 (24%) of 93 patients. This diagnosis was only report-
ed for patients admitted to a PICU and was associated with 
death (OR 7.4, 95% CI, 1.6–37.8; p = 0.004). Six patients 
had a diagnosis of encephalopathy and 2 had a diagnosis of 
myocarditis (Table 2).
Hospital Course and Treatment
The median duration from symptom onset to hospital 
admission was 2 days (IQR 1–5 days), and the median du-
ration from hospitalization to PICU admission was 0 days 
(IQR 0–1 days) for all patients admitted to the PICU. Both 
of these periods were not different between surviving pa-
tients and those who died in the PICU. Among those who 
died who were treated in the PICU, the median time from 
symptom onset to death was 8 days (IQR 3–12 days), and 
the median length of stay in the PICU was 2 days (IQR 0–8 
days) (Table 3).
Among patients admitted to the PICU, oseltamivir was 
administered to 61% (51/84) of the patients; there was no 
difference in its use between survivors and those who died 
(Table 4). Median time from symptom onset to antiviral 
treatment for both groups was 4 days (IQR 1–7 days for 
survivors and 2–8 days for those who died) (Table 3). Oth-
er treatments in the PICU included catecholamines (28/81 
PICU patients, 35%) and mechanical ventilation (56/86, 
65%). Both of these treatments were administered more 
often to those who died (p = 0.007 and p = 0.007, respec-
tively).
Discussion
During the peak phase of the pandemic, active sur-
veillance in pediatric hospitals identiﬁ  ed 93 severe cases 
of pandemic (H1N1) 2009 in children with available in-
formation on prior medical history, course of disease, and 
outcome. When we compared absolute numbers, deaths of 
children caused by pandemic (H1N1) 2009 were reported 
23× more frequently in our study than in a prospective 
study on seasonal inﬂ  uenza (14). In this study, which used 
Figure 2. Date of symptom onset for 86 children 
with severe pandemic (H1N1) 2009, Germany, 
September 21, 2009–February 22, 2010. Only 
children with available information are included.
10
15
20
a
t
i
e
n
t
s
Nonsurvivor
Survivor
0
5
10
15
20
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
N
o
.
 
p
a
t
i
e
n
t
s
Nonsurvivor
Survivor
0
5
10
15
20
0123456789 1 0 1 1 1 2 1 3 1 4
N
o
.
 
p
a
t
i
e
n
t
s
Age, y
Nonsurvivor
Survivor
0
5
10
15
20
0123456789 1 0 1 1 1 2 1 3 1 4
N
o
.
 
p
a
t
i
e
n
t
s
Age, y
Nonsurvivor
Survivor
Figure 3. Age distribution of 93 children with severe pandemic 
(H1N1) 2009, Germany, 2009–2010. Severe Cases of Pandemic (H1N1) 2009 in Children
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an analogous case deﬁ  nition and the same hospital network, 
the deaths of only 2 patients were reported for 3 inﬂ  uenza 
seasons (2005–06, 2006–07, and 2007–08 seasons) in Ger-
many. Similarly, in the United States, more deaths in chil-
dren caused by pandemic (H1N1) 2009 were reported than 
for each of the 3 previous inﬂ  uenza seasons (15).
The higher number of reported deaths caused by pan-
demic (H1N1) 2009 might be partially explained by the 
high level of suspicion among physicians during the pan-
demic, which resulted in more frequent testing and diag-
nosis of inﬂ  uenza. This hypothesis is supported by a pro-
spective study for seasonal inﬂ  uenza in the United States, 
in which only 43% of children admitted to a PICU with 
laboratory-conﬁ  rmed inﬂ  uenza were independently given a 
diagnosis of inﬂ  uenza by the treating physician (16).
Our study indicated a PICU case-fatality rate of 12%, 
which is consistent with results from a study in Canada, 
which reported a case-fatality rate of 7% among 57 case-
patients admitted to a PICU (11). However, case-fatality 
rates for children with pandemic (H1N1) 2009 vary con-
siderably across study sites, as shown in 2 other studies in 
PICU settings. In a cohort of 147 children in Argentina, a 
case fatality rate of 39% was reported (9), which was simi-
lar to a case-fatality rate of 38% in a cohort of 13 patients 
in the United Kingdom (12). Both studies reported a higher 
case-fatality rate than for seasonal inﬂ  uenza. Differences in 
health care organization, including PICU admission crite-
ria, age structure of the cohorts, and selection of study sites 
may partly explain the different ﬁ  ndings.
The incidence rate for severe cases in PICU-admitted 
patients <15 years of age was 8.0 cases/million children, 
which was 5× times as high as the cumulative incidence 
over the 3 previous inﬂ  uenza seasons in the same population 
group reported by Liese et al. (1.7 cases/million children in 
the same age group) (14). This ﬁ  nding is consistent with 
studies from Australia and New Zealand, which showed the 
highest age-speciﬁ  c incidence in this age group (6).
Children <1 year of age represented 20% of our cohort, 
and thus a higher proportion than in the cohort investigated 
in the Netherlands (15%) (13). Special awareness is clear-
ly needed for diagnosing inﬂ  uenza in infants because of 
the variable clinical manifestations in this age group. This 
awareness might be particularly relevant in low-resource 
settings that have limited virologic diagnostic capacities.
In our study, ARDS and pneumonia were the most 
frequent diagnoses among those who died. ARDS was the 
only diagnosis strongly associated with a fatal outcome 
(PICU case-fatality rate 32%). In Argentina, 80% of the 
children in a PICU had ARDS, and this condition was also 
associated with death (9). The frequency of other compli-
cations, which included 6 cases of encephalopathy and 2 
cases of myocarditis did not differ between survivors and 
those who died.
Nine of 93 children in our study had acquired pan-
demic (H1N1) 2009 while hospitalized. The risk for noso-
comial transmission of pandemic (H1N1) 2009 has also 
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Figure 4. Age group distribution of 89 children with severe pandemic 
(H1N1) 2009, by number of underlying chronic medical conditions 
(risk factors), Germany, 2009–2010. Only children with available 
information are listed. Risk factors are chronic respiratory diseases, 
cardiac diseases, immunodeﬁ   ciency, and neurodevelopmental 
disorders.
Table 1. Underlying chronic medical conditions and vaccination status for children with severe pandemic (H1N1) 2009, Germany, 
2009–2010* 
Characteristic Total
Nonsurvivors
not in PICU 
Admitted to PICU 
Survivors Nonsurvivors Subtotal p value  OR (95% CI) 
Underlying chronic medical conditions
  Any  67/89 (75) 4/4 (100)  56/76 (74) 7/9 (78)  63/85 (74)  1 1.3 (0.2–13.3)
  Neurodevelopmental disorders  51/89 (57) 4/4 (100)  40/75 (53) 7/10 (70)  47/85 (55)  0.501  2.0 (0.4–13.1)
  Respiratory disease  31/82 (38) 2/3 (67)  25/70 (36) 4/9 (44)  29/79 (37)  0.718  1.4 (0.3–7.3) 
  Immunodeficiency  13/80 (16) 1/4 (25)  12/67 (18) 0/9 (0)  12/76 (16)  0.339  0.0 (0.0–2.1) 
  Cardiac disease  11/84 (13) 0/4 (0)  9/70 (13)  2/10 (20)  11/80 (14)  0.621  1.7 (0.2–10.6)
Vaccination status in patients >6 mo of age 
  Any influenza  9/56 (16)  0/4 (0)  9/48 (19)  0/4 (0)  9/52 (17)  1 0.0 (0.0–4.7) 
  Pandemic (H1N1) 2009  5/53 (9)  0/4 (0)  5/45 (11)  0/4 (0)  5/49 (10)  1 0.0 (0.0–9.2) 
*Values are no. positive/no. with available information (%) except as indicated. PICU, pediatric intensive care unit; OR, odds ratio; CI, confidence interval. 
ORs were calculated only among patients admitted to the PICU. RESEARCH
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been documented in other studies (17,18). In both of these 
reports, pandemic (H1N1) 2009 was likely transmitted by 
health care workers. Additionally, children with underly-
ing chronic medical conditions might have a higher risk for 
being hospitalized and therefore are particularly exposed to 
the risk for nosocomial infection. As reported for seasonal 
inﬂ  uenza (19,20), this result stresses the need for appropri-
ate preventive strategies in hospital settings, such as early 
use of diagnostic tests and vaccination of health care work-
ers who are involved in the care of patients with risk factors 
for severe disease.
We observed that patients who died had a median time 
in the hospital of 3 days, including 2 days in a PICU. Death 
occurred despite maximum intensive care therapy, as dem-
onstrated by the higher rate of catecholamine treatment and 
mechanical ventilation among those who died. This ob-
served rapid course of fatal disease despite intensive care, 
which was also reported in the United Kingdom (12), un-
derlines the need for prevention.
The proportion of patients having >1 underlying chron-
ic medical condition was high (75% overall) and increased 
with age. Our ﬁ  ndings are consistent with those from a case 
series of 235 hospitalized children with pandemic (H1N1) 
2009 in Canada (median age 4.8 years, range 0–16 years). 
A total of 60% of the patients in this study had >1 under-
lying chronic medical conditions (33% were children <2 
years of age and 72% were older children) (21). Neurode-
velopmental disorders were reported for more than half of 
the children and in more than three fourths of those who 
died. These results are consistent with the results from 
other PICU-setting studies in which neurodevelopmental 
disorders were the ﬁ  rst or second most prevalent risk fac-
tor (9–12). According to the surveillance system for pedi-
atric deaths associated with pandemic (H1N1) 2009 in the 
United States, 92% of the children with high-risk medical 
conditions had neurodevelopmental disorders (22).
In our study, only 5 children had been vaccinated 
against pandemic (H1N1) 2009. Their vaccination dates 
were not given, and it remains unclear whether the inter-
val was sufﬁ  cient to acquire immune protection. A con-
siderable proportion of the patients with investigated cases 
could not beneﬁ  t from immunization because the pandemic 
(H1N1) 2009 vaccine was not publicly available in Germa-
ny until after November 2, 2009, and 17% of all children in 
this study were <6 months of age. In Germany, neurodevel-
opmental disorders had not been explicitly included in the 
Table 2. Clinical diagnosis for children with severe pandemic (H1N1) 2009, Germany, 2009–2010* 
Clinical diagnosis  Total† 
Nonsurvivors
not in PICU† 
Admitted to PICU 
Survivors† Nonsurvivors† Subtotal†  p value  OR (95% CI) 
Pneumonia  70/93 (75)  4/4 (100)  59/78 (76)  7/11 (64)  66/89 (74)  0.465  0.6 (0.1–2.9) 
ARDS 22/93 (24)  0/4 (0)  15/78 (19)  7/11 (64)  22/89 (25)  0.004  7.4 (1.6–37.8) 
Secondary pneumonia  15/93 (16)  0/4 (0)  13/78 (17)  2/11 (18)  15/89 (17)  1 1.1 (0.1–6.3) 
Bronchitis/bronchiolitis 12/93 (13)  1/4 (25)  10/78 (13)  1/11 (9)  11/89 (12)  1 0.7 (0.0–5.8) 
Encephalopathy  6/93 (6)  0/4 (0)  5/78 (6)  1/11 (9)  6/89 (7)  0.558  1.5 (0.0–15.1) 
Sepsis 6/93 (6)  1/4 (25)  5/78 (6)  0/11 (0)  5/89 (6)  1 0.0 (0.0–5.6) 
Status asthmaticus  2/93 (2)  0/4 (0)  2/78 (3)  0/11 (0)  2/89 (2)  1 0.0 (0.0–14.5) 
Febrile seizure  2/93 (2)  0/4 (0)  2/78 (3)  0/11 (0)  2/89 (2)  1 0.0 (0.0–14.5) 
Myocarditis  2/93 (2)  0/4 (0)  1/78 (1)  1/11 (9)  2/89 (2)  0.233  7.7 (0.1–611.9) 
Other diagnosis‡  26/93 (28)  0/4 (0)  21/78 (27)  5/11 (45)  26/89 (29)  0.287  2.3 (0.5–9.9) 
*Values are no. positive/no. with available information (%) except as indicated. PICU, pediatric intensive care unit; OR, odds ratio; CI, confidence interval; 
ARDS, acute respiratory distress syndrome. ORs were calculated only among the cases admitted to the PICU. 
†Children may have had >1 diagnosis. 
‡Acute exacerbation of a chronic disease or new diagnosis. 
Table 3. Clinical course for children with severe pandemic (H1N1) 2009, Germany, 2009–2010* 
Characteristic Total
Nonsurvivors
not in PICU 
Admitted to PICU 
Survivors Nonsurvivors Subtotal p value
Time course of illness, d 
  Symptom to hospital admission  77, 2 (1–5)  3, 1 (1–2)  65, 2 (1–5)  9, 1 (1–3)  74, 2 (1–5)  0.700 
  Hospitalization to PICU  
 admission 
74, 0 (0–1)  NA 65, 0 (0–1)  9, 1 (0–3)  74, 0 (0–1)  0.236 
  PICU length of stay  80, 8 (3–17)  NA 69, 9 (3–18)  11, 2 (0–8)  80, 8 (3–17)  NC 
  Hospital length of stay  83, 14 (5–23) 3, 5 (3–12)  69, 16 (7–25)  11, 3 (2–12)  80, 14.5 (5.5–23.5)  NC 
  Symptom onset to outcome†  85, 16 (8–26) 4, 5.5 (5–9.5) 72, 18.5 (10.5–29.5)  9, 8 (3–12)  81, 17 (8–27)  NC 
Time to treatment, d 
  Symptom onset to oseltamivir  
 treatment 
45, 4 (1–7)  1, 4‡  39, 4 (1–7)  5, 4 (2–8)  44, 4 (1–7)  0.551 
*Values given are total no. with available information, median (IQR), except as indicated. PICU, pediatric intensive care unit; IQR, interquartile range; NA, 
not applicable (not admitted to PICU); NC, not compared because of different outcomes (release for survivors and death for nonsurvivors). 
†Including patients with hospital-acquired pandemic (H1N1) 2009 infection. 
‡Only 1 observation. Severe Cases of Pandemic (H1N1) 2009 in Children
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chronic medical conditions in the vaccination recommen-
dations for seasonal inﬂ  uenza (23) and were only speciﬁ  ed 
in recommendations for pandemic (H1N1) 2009 vaccine 
(24). In contrast, in the United States, neurodevelopmental 
disorders had already been recognized as a risk factor for 
seasonal inﬂ  uenza in 2005 (25).
Recent reports on adults and children with pandemic 
(H1N1) 2009 suggested that oseltamivir therapy beneﬁ  t-
ted patients with severe cases. Early treatment within 2 
days after symptom onset was statistically associated with 
a lower risk for ICU admission and death in hospitalized 
pandemic (H1N1) 2009 patients (n = 272; median age 21 
years) than with later treatment (26). In our study, the me-
dian time to oseltamivir treatment was 4 days and did not 
differ between survivors and those who died. Therefore, 
our study might not have been able to detect the beneﬁ  t 
of this treatment. Nevertheless, this ﬁ   nding should be 
viewed with caution because our study was not designed 
to evaluate the effectiveness of oseltamivir for treatment 
of children with pandemic (H1N1) 2009. However, 1 ICU-
setting study (n = 58; median age 44 years) suggested a 
beneﬁ  t for patients who were treated with oseltamivir >48 
hours after illness onset (7).
The representativeness of our study was assessed by 
comparing our data with those from the national databas-
es. First, the timeline of our cases was compared with the 
Praxis Index, which derives from the syndromic surveil-
lance system of the national working group on inﬂ  uenza 
and accounts for all notiﬁ  cations of inﬂ  uenza-like illness 
cases in Germany. The Praxis Index curve and the epide-
miologic curve of patients investigated in our study show 
similar shapes. Second, of the 15 identiﬁ  ed deaths in our 
study, 14 could be matched with the 29 deaths in children 
<15 years of age reported in the National Surveillance Sys-
tem. This difference might be explained by the fact that 
only children admitted to pediatric hospitals were captured 
in our study. Because our study was a nationwide study, 
the 93 cases originated from 55 hospitals in 14 of the 16 
Federal States of Germany.
Our study has several limitations. These limitations 
include potential underreporting, although this might have 
been minimized by increased awareness during the inﬂ  u-
enza pandemic in Germany. In addition, patients with in-
ﬂ  uenza could not be included when the questionnaires were 
not returned despite written reminders. Another limitation 
might be that not all children are hospitalized in pediatric 
hospitals. However, patients with severe cases requiring in-
tensive care would likely have been transferred to a PICU 
and thus should have been captured in our study. This sug-
gestion is supported by the fact that 11 patients had been 
transferred from other hospitals. An additional limitation 
might be that knowledge of clinical features of patients was 
only based on information provided in the questionnaires. 
Furthermore, ascertainment of underlying chronic medical 
conditions was not standardized and may differ from 1 phy-
sician to another. Because the survey instrument captured 
temporal information in days, the time from symptom onset 
to initiation of treatment could not be calculated in hours. 
Finally, even with an unexpected high number of reported 
severe cases, the total number of deaths in PICUs was too 
small to perform a multivariable analysis for factors associ-
ated with death.
This study identiﬁ  ed a considerable number of severe 
cases of pandemic (H1N1) 2009 among children in Germa-
ny, conﬁ  rming observations in the Americas. Our results 
stress the role of underlying risk factors, especially neu-
rodevelopmental disorders, in children with severe cases 
of pandemic (H1N1) 2009. The results also indicate that 
measures that would prevent severe disease and adverse 
outcomes in children, including vaccination and other pre-
ventive measures, as well as early diagnosis and prompt 
treatment of this infection, are not used to their full extent 
despite availability of maximum care resources. 
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Table 4. Treatment administered to children with severe pandemic (H1N1) 2009, Germany, 2009–2010* 
Treatment Total
Nonsurvivors
not in PICU 
Admitted to PICU 
Survivors Nonsurvivors Subtotal p value  OR (95% CI) 
Oseltamivir 53/88 (60)  2/4 (50)  44/74 (59)  7/10 (70)  51/84 (61)  0.733  1.6 (0.3–10.2) 
Antimicrobial drug  80/91 (88)  4/4 (100)  67/77 (87)  9/10 (90)  76/87 (87)  1 1.3 (0.2–64.7) 
Catecholamine 28/85 (33)  0/4 (0)  20/70 (29)  8/11 (73)  28/81 (35)  0.007  6.7 (1.4–41.8) 
Mechanical ventilation  56/90 (62)  0/4 (0)  45/75 (60)  11/11 (100)  56/86 (65)  0.007  NA (1.8–NA) 
*Values are no. positive/no with available information (%) except as indicated. PICU, pediatric intensive care unit; OR, odds ratio; CI, confidence interval, 
NA, not applicable. RESEARCH
192  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 2, February 2011
References
    1.   World Health Organization. Pandemic (H1N1) 2009—update 
101. 2010 May 21 [cited 2010 May 22]. http://www.who.int/csr/
don/2010_05_21/en/print.html
  2.   Robert  Koch  Institute.  Inﬂ  uenza⎯weekly report, Germany, 
2010 [in German] [cited 2010 May 19]. http://inﬂ  uenza.rki.de/
Wochenberichte/2009_2010/2010-19.pdf
  3.   Centers for Disease Control and Prevention. 2009 pandemic inﬂ  u-
enza A (H1N1) virus infections—Chicago, Illinois, April–July 2009. 
MMWR Morb Mortal Wkly Rep. 2009;58:913–8.
  4.   Kelly H, Grant K. Interim analysis of pandemic inﬂ  uenza (H1N1) 
2009 in Australia: surveillance trends, age of infection and effective-
ness of seasonal vaccination. Euro Surveill. 2009;14:pii:19288. 
  5.   European Center for Disease Prevention and Control. Risk assess-
ment. Pandemic H1N1 2009 [cited 2009 Dec 20]. http://ecdc.europa.
eu/en/healthtopics/H1N1/Documents/1001_RA_091217.pdf
  6.   Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, 
et al. Critical care services and 2009 H1N1 inﬂ  uenza in Australia 
and New Zealand. N Engl J Med. 2009;361:1925–34. DOI: 10.1056/
NEJMoa0908481
  7.   Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-
Perez L, de la Torre A, et al. Critically ill patients with 2009 inﬂ  u-
enza A(H1N1) in Mexico. JAMA. 2009;302:1880–7. DOI: 10.1001/
jama.2009.1536
  8.   Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, 
et al. Critically ill patients with 2009 inﬂ  uenza A(H1N1) infection in 
Canada. JAMA. 2009;302:1872–9. DOI: 10.1001/jama.2009.1496
  9.   Farias JA, Fernandez A, Monteverde E, Vidal N, Arias P, Montes 
MJ, et al. Critically ill infants and children with inﬂ  uenza A (H1N1) 
in pediatric intensive care units in Argentina. Intensive Care Med. 
2010;36:1015–22. DOI: 10.1007/s00134-010-1853-1
10.   Lockman JL, Fischer WA, Perl TM, Valsamakis A, Nichols DG. 
The critically ill child with novel H1N1 inﬂ  uenza A: a case se-
ries. Pediatr Crit Care Med. 2010;11:173–8. DOI: 10.1097/
PCC.0b013e3181ccedae
11.   Jouvet P, Hutchison J, Pinto R, Menon K, Rodin R, Choong K, et al. 
Critical illness in children with inﬂ  uenza A/pH1N1 2009 infection 
in Canada. Pediatr Crit Care Med. 2010;11:603–9. DOI: 10.1097/
PCC.0b013e3181d9c80b
12.   Lister P, Reynolds F, Parslow R, Chan A, Cooper M, Plunkett A, et 
al. Swine-origin inﬂ  uenza virus H1N1, seasonal inﬂ  uenza virus, and 
critical illness in children. Lancet. 2009;374:605–7. DOI: 10.1016/
S0140-6736(09)61512-9
13.   van Zwol A, Witteveen R, Markhorst D, Geukers VG. Clinical fea-
tures of a Dutch cohort of critically ill children due to the 2009 new 
inﬂ  uenza A H1N1 pandemic. Clin Pediatr (Phila). 2010 Sep 13; 
[Epub ahead of print]. DOI: 10.1177/0009922810381426
14.   Liese J, Grote V, Streng A. Schwere intensivestationspﬂ  ichtige In-
ﬂ  uenza-Virus-Infektionen und Inﬂ  uenza-assoziierte Todesfälle bei 
Kindern und Jugendlichen unter 16 Jahren (Erfassung von Inﬂ  u-
enzafällen auf Intensivstationen bei Kindern mittels ESPED). 2009 
Mar 19 [cited 2010 Apr 22]. http://www.esped.uni-duesseldorf.de/
jabe2008.pdf
15.   Centers for Disease Control and Prevention. Flu activity and surveil-
lance: number of inﬂ  uenza-associated pediatric deaths by week of 
death, 2006–2007 to present. 2010 [cited 2010 May 6]. http://www.
cdc.gov/ﬂ  u/weekly/weeklyarchives2009-2010/weekly20.htm
16.   Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, 
Iwane MK, et al. The underrecognized burden of inﬂ  uenza in young 
children. N Engl J Med. 2006;355:31–40. DOI: 10.1056/NEJM
oa054869
17.   Chironna M, Tafuri S, Santoro N, Prato R, Quarto M, Germinario 
CA. A nosocomial outbreak of 2009 pandemic inﬂ  uenza A(H1N1) in 
a paediatric oncology ward in Italy, October–November 2009. Euro 
Surveill. 2010;15:pii:19454. 
18.   Cunha BA, Thekkel V, Krilov L. Nosocomial swine inﬂ  uenza 
(H1N1) pneumonia: lessons learned from an illustrative case. J Hosp 
Infect. 2010;74:278–81. DOI: 10.1016/j.jhin.2009.08.024
19.   Oliveira EC, Lee B, Colice GL. Inﬂ   uenza in the inten-
sive care unit. J Intensive Care Med. 2003;18:80–91. DOI: 
10.1177/0885066602250368
20.   Maltezou HC, Drancourt M. Nosocomial inﬂ  uenza in children. J Hosp 
Infect. 2003;55:83–91. DOI: 10.1016/S0195-6701(03)00262-7
21.   Bettinger JA, Sauve LJ, Scheifele DW, Moore D, Vaudry W, Tran D, 
et al. Pandemic inﬂ  uenza in Canadian children: a summary of hos-
pitalized pediatric cases. Vaccine. 2010;28:3180–4. DOI: 10.1016/j.
vaccine.2010.02.044
22.   Centers for Disease Control and Prevention. Surveillance for pediat-
ric deaths associated with 2009 pandemic inﬂ  uenza A (H1N1) virus 
infection—United States, April–August 2009. MMWR Morb Mor-
tal Wkly Rep. 2009;58:941–7.
23.   German Standing Vaccination Committee (STIKO). Epidemiologi-
cal Bulletin. 27. July 2009 [in German] [cited 2010 May 6] http://
www.rki.de/cln_160/nn_1378492/DE/Content/Infekt/EpidBull/
Archiv/2009/30__09,templateId=raw,property=publicationFile.
pdf/30_09.pdf
24.   German Standing Vaccination Committee (STIKO). Epidemiologi-
cal Bulletin—vaccination against new inﬂ  uenza A (H1N1). 2009 
Dec 14 [in German] [cited 2010 May 6]. http://www.rki.de/cln_160/
nn_1270420/DE/Content/Infekt/EpidBull/Archiv/2009/50__09,
templateId=raw,property=publicationFile.pdf/50_09.pdf
25.   Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention 
and control of inﬂ  uenza. Recommendations of the Advisory Com-
mittee on Immunization Practices (ACIP). MMWR Recomm Rep. 
2005;54:1–40.
26.  Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie 
J, et al. Hospitalized patients with 2009 H1N1 inﬂ  uenza in the Unit-
ed States, April–June 2009. N Engl J Med. 2009;361:1935–44. DOI: 
10.1056/NEJMoa0906695
Address for correspondence: Mathias Altmann, Department for Infectious 
Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, 
Postfach 65 02 61, 13302 Berlin, Germany; email: altmannm@rki.de